Vaccines and Public Health · global
IAVI receives US$36 million in funding to advance single-dose Bundibugyo Ebola vaccine
Amid the outbreak in the Democratic Republic of the Congo, the funding will connect vaccine manufacturing, a Phase 1 human trial and subsequent field evaluation during the outbreak, while also supporting an updated candidate targeting the 2026 viral variant; evidence of protection currently remains limited to animal studies.
One gap in the response to Ebola outbreaks is that there is still no approved vaccine or dedicated treatment for Bundibugyo virus. As the outbreak in the Democratic Republic of the Congo continues, the nonprofit biomedical research organization IAVI announced on October 28 that it had received an initial US$36 million award from the US Biomedical Advanced Research and Development Authority (BARDA) to advance a single-dose vaccine candidate toward human evaluation and supply readiness.
The funding is part of a contract worth up to US$99 million and should not be taken to mean that the full amount has been secured. According to IAVI’s announcement and Reuters reporting, the award covers manufacturing doses needed for clinical testing and outbreak response, early-stage clinical trials and related regulatory work; the contract also includes options to expand production to support future outbreak preparedness needs.
According to IAVI’s announcement issued through ACCESS Newswire, the development pathway begins with a Phase 1 trial, with the aim of subsequently participating in a planned ring vaccination trial in the Democratic Republic of the Congo. The single-dose design could reduce the follow-up and delivery burden associated with multiple vaccinations, but the announcement provided no human trial results, and subsequent field evaluation remains planned.
The vaccine candidate uses a recombinant vesicular stomatitis virus (rVSV) platform. IAVI said studies in nonhuman primates have demonstrated protection, but the candidate has not yet been evaluated in humans. The animal studies provide a basis for entering clinical development, but they cannot yet answer questions about safety in humans, the degree of protection or how long protection might last.
Changes in the virus itself are another issue this funding will address. The vaccine candidate currently in early development is based on the strain from the 2007 outbreak, and the new funding will also support production of an updated version targeting the variant from the 2026 outbreak. This means that, alongside advancing the existing candidate, the team must assess how the immune response it elicits relates to the currently circulating virus; whether the updated design provides better protection still requires confirmation through research.
The division of manufacturing responsibilities will gradually connect the investigational vaccine to potential stockpile supply. Hilleman Laboratories will manufacture doses for initial clinical use. If BARDA exercises the relevant options, subsequent plans call for SK bioscience to lead production scale-up, IDT Biologika to handle filling and finished-product manufacturing for stockpile doses, and MSD to provide technical assistance. IAVI is responsible for overall development and clinical and regulatory strategy.
The investment also addresses supply needs that have received less attention under existing funding: work supported by the Coalition for Epidemic Preparedness Innovations (CEPI) focuses on accelerating outbreak response, while BARDA is investing further in manufacturing readiness and stockpile supply. For this vaccine, the funding enables human trials and production preparations to proceed in parallel; whether it can become a tool available for use during outbreaks still depends on forthcoming clinical evidence and regulatory evaluation.